Medytox reported on the 13th that its consolidated operating profit for the previous year was 20 billion won, an increase of 15.6% compared to the previous year. During the same period, sales rose by 3.4% year-on-year to 228.6 billion won, marking a record high for the second consecutive year.
According to the company, the growth of its main business areas, hyaluronic acid (HA) fillers and the neurodermis cosmetic Neuraderm, led to this record sales figure. The reduction in commissions also improved operating profit. Last year, net profit rose by 63.5% year-on-year, reaching 15.8 billion won.
In the case of the filler institutional sector, domestic and overseas sales both grew by 17% and 5%, respectively, compared to the same period last year. However, the toxin institutional sector saw a decline in domestic and overseas sales of 4% and 9%, respectively, due to a decrease in the operation rate of the first factory in the third quarter of last year and delays in the re-certification of pharmaceutical manufacturing and quality control standards (GMP) in some exporting countries in the fourth quarter.
Medytox plans to focus on the global expansion of its subsidiary Neumeco's next-generation toxin product, Neurux. Having received approval in Peru and Thailand last year, Neurux is aiming for approval in over 20 countries this year. By adding manufacturing facility E in Osong's third factory last year, Medytox established a mass production system for Neurux. The company's flagship product, Coretox, has also begun mass supply, and market share expansion is expected. The company is also anticipating steady sales growth for HA fillers Neuramis and Attiere.
A Medytox official noted, "2025 will be a crucial point for Medytox to leap as a global corporation, with the full-scale overseas expansion of Neurux and the application for U.S. FDA approval of the next-generation non-animal liquid toxin product MT10109L. We will continue to develop a pipeline with differentiated competitiveness, including PF30 in pre-filled syringe (PFS) form and the genetically modified toxin product 'MT951.'"